Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lymphoma, B-Cell Clinical Trials

A listing of Lymphoma, B-Cell medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (598) clinical trials

Detection and Characterization of Residual Masses in Lymphomas

Imaging biomarkers are important tools for the detection and characterization of cancers as well as for monitoring the response to therapy. "Whole-body" molecular imaging, in particular using 18-Fluorodeoxyglucose-PET, has been proven useful in the evaluation and management of lymphoma patients. FDG-PET has evolved as a valuable biomarker in aggressive lymphomas, ...

Phase N/A

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To evaluate the safety of JCAR014 in combination with durvalumab in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). II. To determine the maximum tolerated dose (MTD) of durvalumab in combination with JCAR014. III. To characterize the pharmacokinetic (PK) profile of JCAR014. SECONDARY OBJECTIVES: I. To ...

Phase

Treatment for Advanced B-Cell Lymphoma

To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to ...

Phase

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR Advanced B-Cell NHL ALL and CLL (SAGAN)

Patients will give the investigators blood to make CD19 CD28 (with and without CD137) chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the T cells, investigators will take blood (or blood from a donor) and stimulate it with growth factors to make the ...

Phase

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

The incidence of DLBCL is increasing and with an expanding elderly population, the incidence will continue to rise. Given that about 40% of cases of DLBCL occur in patients aged over 70 and the number of co-mobilities increases with age, research to investigate the optimal treatment of DLBCL in this ...

Phase

Kappa-CD28 T Lymphocytes Chronic Lymphocytic Leukemia B-cell Lymphoma or Multiple Myeloma CHARKALL

To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) separate blood collections of 120 ml (up to 8 tablespoonfuls) of blood. To get the kappa antibody (with CD28) to ...

Phase

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) of adoptive cellular immunotherapy using ex vivo transduced and expanded autologous T cells expressing a third (3rd)-generation fully human CD20-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma (B-NHL). SECONDARY OBJECTIVES: I. To evaluate ...

Phase

Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Study Drug Administration: Each cycle is 28 (+/- 7) days. If participant is found to be eligible to take part in this study, participant will receive inotuzumab ozogamicin by vein over about 1 hour on Days 1, 8, and 15 of Cycle 1 and Days 1 and 8 of Cycles ...

Phase

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy

Phase

Phase 1/2 Study of the Combination of Pixantrone Etoposide Bendamustine and in CD20 Positive Tumors Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamsutine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.

Phase